Amgen Inc
I · AI-analyse
In het kort
Amgen discovers, develops, manufactures, and delivers prescription medicines for serious illnesses including rheumatoid arthritis (Enbrel), high cholesterol (Repatha), osteoporosis (Prolia, Evenity), cancer (Blincyto, Kyprolis, Vectibix), and rare diseases like thyroid eye disease (Tepezza) [Yahoo Finance]. The company sells through doctors' offices, hospitals, dialysis centers, and pharmacies, primarily via pharmaceutical wholesalers [Yahoo Finance].
Amgen is the world's largest independent biotech company, developing and selling medicines for cancer, autoimmune diseases, osteoporosis, and rare conditions [Yahoo Finance]. The company generates $36.7B in annual revenue with strong margins, but faces serious safety concerns around its drug Tavneos, which has been linked to 20 deaths and 22 liver injuries in Japan [Seeking Alpha]. Recent leadership changes include the retirement of CFO Peter Griffith, who will be replaced by returning veteran Thomas Dittrich [Yahoo Finance].
Amgen is financially healthy with strong cash generation and reasonable leverage, earning a 7.4/10 health score [Yahoo Finance].
Sentinellis-score
7.4/10
Financially healthy
Marktkapitalisatie
$178.6B
Omzet (12 maanden)
$36.7B
II · Recent nieuws
Wat de koers bewoog
6 stories · ranked by relevance
- macro2026-05-19
AMGEN ANNOUNCES RETIREMENT OF CHIEF FINANCIAL OFFICER PETER GRIFFITH
Yahoo Finance
- macro2026-05-18
Amgen (AMGN) Gets Price Target Cut at Piper Sandler Despite Long-Term Growth Optimism
Yahoo Finance
- macro2026-05-18
Middle East and Africa Wearable Injectors Market Trends and Forecast Report 2026-2035 Featuring Amgen, BD, Biocon, Gerresheimer, Insulet, J&J, Medtronic, Roche, West Pharmaceutical, Ypsomed
Yahoo Finance
- macro2026-05-18
Amgen Japanese Partner Urges Caution On Tavneos Use
Yahoo Finance
- macro2026-05-15
Is It Time To Reassess Amgen (AMGN) After Strong Multi Year Share Price Gains
Simply Wall St
- macro2026-05-15
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
Zacks
Premium · gratis met elk account
Tavneos faces serious safety scrutiny in Japan after being linked to 20 deaths and 22 liver injuries, which could lead to restricted use, regulatory action, or lawsuits in other markets where Amgen sells the drug [Seeking Alpha]
Risico's
4
Kansen
5
Waarschuwingssignalen
3
Leiding
10
Nog 21 bevindingen in het volledige rapport — gratis met elk account.
Ontgrendel de volledige analyse van Amgen Inc
Maak een gratis account voor het volledige AI-rapport met bronvermelding in de tekst.
- 4 risico's, 5 kansen en 3 waarschuwingssignalen — elk met zijn bron
- Meer dan 100 financiële cijfers met grafieken en vergelijkingen
- Volledige nieuwssamenvattingen met bronlinks
- Directie en beloning
- PDF-export voor offline
III · Vergelijkbare bedrijven
Misschien ook interessant
Same sector · Healthcare or comparable health
Op je volglijst zetten?